Expert Highlights Next Steps to Evolve the Treatment Landscape of Urothelial Cancer
Peter Grivas, MD, PhD, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.
Peter Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor of oncology, University of Washington, Seattle Cancer Care Alliance, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.
Grivas says we need more effective therapies. Currently, only chemotherapy and immunotherapy agents are approved, but there are trials investigating the role of FGFR inhibitors and antibody-drug conjugates. The FDA has granted a breakthrough therapy designation to erdafitinib, an FGFR inhibitor, and the data has looked promising so far.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
